Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MGLL | Q99685 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30288275 | 1.00 | TSHR (0.59) | TSHRMGLLBRD4CA2FDPS | |
| SCHEMBL28488286 | 0.93 | TSHR (0.48) | TSHRMGLLBRD4CA2FDPS | |
| SCHEMBL16285528 | 0.87 | TSHR (0.45) | TSHRMGLLBRD4CA2FDPS | |
| SCHEMBL16285573 | 0.87 | L3MBTL1 (0.47) | TSHRMGLLKDM4EALDH1A1SYK | |
| SCHEMBL16285546 | 0.87 | TSHR (0.45) | TSHRMGLLBRD4CA2FDPS | |
| SCHEMBL22293393 | 0.86 | TSHR (0.48) | TSHRMGLLCA2FDPSMMP8 | |
| Biphenyl SCHEMBL8911205 | 0.85 | TSHR (0.82) | TSHRMGLLALDH1A1 | |
| SCHEMBL23576809 | 0.85 | NPC1 (0.42) | TSHRMGLLBRD4CNR1HDAC6 | |
| SCHEMBL24617986 | 0.85 | BRD4 (0.53) | TSHRMGLLBRD4CNR1KDM4E | |
| SCHEMBL24272977 | 0.84 | TSHR (0.56) | TSHRMGLLCNR1MAOAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4063368-B1 | NITROGEN-CONTAINING COMPOUND AND ELECTRONIC ELEMENT COMPRISING SAME, AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MAT CO LTD (CN) | 2024-06-26 | — | — | EP | disclosed |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230337534-A1 | NITROGEN-CONTAINING COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS THEREOF | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| WO-2023185078-A1 | ORGANIC COMPOUND, ELECTRONIC ELEMENT AND ELECTRONIC DEVICE | 陕西莱特光电材料股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023070987-A9 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME, AND ELECTRONIC APPARATUS | 陕西莱特光电材料股份有限公司 | 2023-08-24 | — | — | WO | disclosed |
| EP-3720858-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF HEART FAILURE AND DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230171979-A1 | ORGANIC LIGHT EMITTING DIODE AND ORGANIC LIGHT EMITTING DEVICE HAVING THEREOF | LG DISPLAY CO., LTD. (KR) | 2023-06-01 | — | — | US | disclosed |
| WO-2023087557-A1 | ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC DEVICE | 陕西莱特光电材料股份有限公司 | 2023-05-25 | — | — | WO | disclosed |
| WO-2023070987-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME, AND ELECTRONIC APPARATUS | 陕西莱特光电材料股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| WO-2003099776-A1 | CALCIUM RECEPTOR MODULATING ARYLALKYLAMINES | AMGEN INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-6552022-B1 | Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels | SMITHKLINE BEECHAM CORPORATION | 2003-04-22 | — | — | US | disclosed |
| EP-1286670-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-03-05 | — | — | EP | disclosed |
| EP-0923551-B1 | 4-AMINOETHOXY INDOLONE DERIVATIVES | AMERICAN HOME PROD (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001097810-A2 | USE OF THERAPEUTIC BENZAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-12-27 | — | — | WO | disclosed |
| EP-1135378-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-09-26 | — | — | EP | disclosed |
| WO-2000032582-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-08 | — | — | WO | disclosed |
| EP-0923551-A1 | 4-AMINOETHOXY INDOLONE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5817690-A | ANTIDOPAMINE AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-10-06 | — | — | US | disclosed |
| WO-1998008819-A1 | 4-AMINOETHOXY INDOLONE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | TSHR 1965/4885MGLL 1655/4885BRD4 1039/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | TSHR 3398/4885MGLL 4568/4885BRD4 180/4885 |
| US-20230337534-A1 | NITROGEN-CONTAINING COMPOUND, AND ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS THEREOF | NUDC, SLC29A2, SLC6A19 | TSHR 4767/4885MGLL 3498/4885BRD4 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.